DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 주식 보고서

시가총액: CN¥17.4b

DaShenLin Pharmaceutical Group 미래 성장

Future 기준 확인 3/6

DaShenLin Pharmaceutical Group (는) 각각 연간 24.9% 및 16.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 25.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.5% 로 예상됩니다.

주요 정보

24.9%

수익 성장률

25.1%

EPS 성장률

Consumer Retailing 수익 성장41.6%
매출 성장률16.7%
향후 자기자본 수익률17.5%
애널리스트 커버리지

Good

마지막 업데이트19 Nov 2024

최근 미래 성장 업데이트

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

수익 및 매출 성장 예측

SHSE:603233 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202638,4491,6762,3423,97012
12/31/202532,7301,4142,0533,54612
12/31/202426,9491,0712,7173,2767
9/30/202426,5398501,4883,202N/A
6/30/202425,8859071,6343,464N/A
3/31/202425,3361,0682,0493,648N/A
12/31/202324,5311,1661,3773,174N/A
9/30/202324,1541,2872,0554,160N/A
6/30/202323,5191,2391,8463,815N/A
3/31/202322,5181,1482,5293,843N/A
12/31/202221,2481,0362,7223,757N/A
9/30/202219,2228961,2602,411N/A
6/30/202218,4258601,0272,237N/A
3/31/202217,3778353841,708N/A
12/31/202116,7597912601,555N/A
9/30/202116,4461,0136821,833N/A
6/30/202115,6971,1131,0972,066N/A
3/31/202115,2801,1221,2862,145N/A
12/31/202014,5831,0621,1621,954N/A
9/30/202013,5931,0141,4301,966N/A
6/30/202012,8299171,2291,759N/A
3/31/202011,9257991,2251,779N/A
12/31/201911,1417031,2061,708N/A
9/30/201910,6016741,1721,462N/A
6/30/201910,0296248521,285N/A
3/31/20199,4045696131,119N/A
12/31/20188,859532319874N/A
9/30/20188,421522-118663N/A
6/30/20188,003515N/A553N/A
3/31/20187,718505N/A511N/A
12/31/20177,421475N/A648N/A
9/30/20176,992462N/A545N/A
6/30/20176,824458N/A497N/A
3/31/20176,545433N/A502N/A
12/31/20166,274430N/A496N/A
6/30/20165,681427N/A406N/A
3/31/20165,464415N/A445N/A
12/31/20155,265395N/A469N/A
12/31/20144,545266N/A449N/A
12/31/20133,707197N/A288N/A

애널리스트 미래 성장 예측

수입 대 저축률: 603233 의 연간 예상 수익 증가율( 24.9% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 603233 의 연간 수익( 24.9% ) CN 시장( 26.3% 보다 느리게 성장할 것으로 예상됩니다. 26.3% 연간).

고성장 수익: 603233 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: 603233 의 수익(연간 16.7% ) CN 시장( 13.9% 보다 빠르게 성장할 것으로 예상됩니다. 13.9% 연간).

고성장 수익: 603233 의 수익(연간 16.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: 603233 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 17.5 %).


성장 기업 발견